抑郁癥是一種慢性復(fù)發(fā)性精神疾病，傳統(tǒng)抗抑郁藥通常需要連續(xù)幾周的治療才能發(fā)揮顯著的治療效果。N-甲基-D-天冬氨酸受體拮抗劑氯胺酮的上市為速效抗抑郁藥物的研發(fā)打開了一個全新的視角，膽堿能受體阻滯劑東莨菪堿、5-HT2A受體激動劑賽洛西賓也表現(xiàn)出快速抗抑郁的作用潛力。歸納了谷氨酸能速效抗抑郁藥、膽堿能受體拮抗劑、5-HT2A受體激動劑（致幻劑）速效抗抑郁藥的藥理學(xué)靶點研究，分析了新靶點的可能策略，以期對未來抗抑郁藥物研究方向有所啟示。

Depression is a chronic recurrent mental illness, and traditional antidepressants usually require several weeks of continuous use to achieve significant therapeutic effects. The launch of N-methyl-D-aspartate receptor antagonist ketamine has opened up a new perspective for the development of rapid acting antidepressants. Cholinergic receptor blocker scopolamine and 5-HT2A receptor agonist psilocybine have also shown potential for rapid antidepressant effects. This article summarizes the pharmacological target of rapid acting antidepressants glutamic acid rapid acting antidepressants, cholinergic receptor antagonists, and 5-HT2A receptor agonists (hallucinogens), analyzes possible strategies for new targets, with the aim of providing insights for future research on antidepressants.

R971

四川省區(qū)域創(chuàng)新合作任務(wù)（2020YFQ0010）